<DOC>
	<DOCNO>NCT00089414</DOCNO>
	<brief_summary>This study determine whether uninterrupted treatment birth control pills several menstrual cycle prevents severe premenstrual syndrome ( PMDD ) . Previous study show hormone estrogen progesterone regulate mood woman MRMD . This study use various treatment regimen birth control pill placebo ( sugar pill ) clarify relationship among estrogen progesterone , menstrual cycle , mood . Healthy woman 18 45 year age menstruate may eligible 15-week study . Candidates screen physical examination , blood urine test , electrocardiogram , 3 month symptoms rating confirm MRMD . Participants randomly assign one three treatment group . Group 1 take birth control pill every day three occasion take placebo capsule . Group 2 take birth control pill day three occasion take placebo capsule . Group 3 take birth control pill every day three occasion take another medication call CDB-2914 cause menstrual bleeding occur . Participants come NIH clinic every week blood test measurement vital sign ( blood pressure , pulse , temperature ) complete symptom rating scale . Subjects develop breakthrough bleeding ( menstruation earlier expect ) transvaginal ultrasound . For procedure , probe insert vagina 10 minute . The probe give receives sound wave use form picture endometrium ( line uterus ) .</brief_summary>
	<brief_title>Treatment Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives</brief_title>
	<detailed_description>Results previous protocol ( # 90-M-0088 92-M-0174 ) demonstrate woman menstrually-related mood disorder ( MRMD ) , woman lack disorder , experience mood deterioration within approximately one two week exposure either estradiol progesterone context gonadal suppression ( induce use depot gonadotropin release hormone agonist leuprolide acetate ) . Preliminary result protocol 00-M-0103 suggest hormone-induced depression occur consequent change gonadal steroid level simple exposure basal level critical threshold . Additionally , continue administration hormone three month result symptoms subsequent initial precipitate episode . These data suggest potential therapeutic benefit extend oral contraceptive ( OC ) regimens reduced pill-free interval MRMD minimize mood destabilizing effect change hormone level . In protocol examine whether effect 15 week continuous oral contraceptive administration cause remission symptom woman MRMD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>INCLUSION CRITERIA ( protocol 81M0126 follow ) : Subjects meet criterion MRMD healthy ( physical exam , normal pelvic exam pap smear , normal lab value ) medication free include study . Oral contraceptive ( CDB2914 arm # 3 ) administer subject significant clinical laboratory abnormality . EXCLUSION CRITERIA : Any patient current axis I psychiatric diagnosis exclude participate protocol . Subjects take psychotropic agent ( e.g . antidepressant , anxiolytic mood stabilizer ) likewise exclude study . Women receive glucocorticoid megestrol therapy within last year ( thus may experience residual suppression compensatory HPA axis response CDB2914induced glucocorticoid receptor antagonism ) also exclude , albeit almost entirely theoretical ground . Women chronic medical condition take medication exclude . Women medical condition take chronic medication may increase serum potassium level also exclude . Those patient would uncomfortable extend length menstrual cycle enrol study either offer participation another study outside referral treatment community . The following condition constitute contraindication treatment continuous oral contraception use progesterone antagonist , CDB2914 , preclude patient 's participate protocol : history endometriosis , recent , rapid growth uterine fibroid tumor ( define double size six month period ) ; diagnosis illdefined , obscure pelvic lesion , particularly undiagnosed ovarian enlargement ; hepatic disease manifest abnormal liver function test ; history breast carcinoma ; history pulmonary embolism phlebothrombosis ; undiagnosed vaginal bleeding ; porphyria ; history malignant melanoma ; history cholecystitis pancreatitis ; history hypercholesterolemia , hypertension , diabetes , renal disease ; recurrent migraine headache ( great equal 3 per year ) woman 35 old ; pregnancy lactation ; cigarette smoke woman 35 old , 10 cigarette per day woman 35 ; use oral , injectable , inhaled glucocorticoid megestrol within last year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Menstrual Cycle</keyword>
	<keyword>Gonadal Steroids</keyword>
	<keyword>Ethinyl Estradiol</keyword>
	<keyword>Drospirenone</keyword>
	<keyword>Menstrually Related Mood Disorder</keyword>
	<keyword>MRMD</keyword>
</DOC>